{"wiki_id": "http://www.wikidata.org/entity/Q3296254", "itemLabel": "Mary Broadfoot Walker", "itemDescription": "British physician", "wikipedia_url": "https://en.wikipedia.org/wiki/Mary_Broadfoot_Walker", "wikipedia_page": {"main": "Mary Broadfoot Walker (17 April 1888 \u2013 13 September 1974) was a Scottish physician who first demonstrated the effectiveness of physostigmine in the treatment of the condition myasthenia gravis, a disease relating to muscle weakness. She was also the first to recognise the association between familial periodic paralysis and low blood potassium levels.", "link_mentions": [{"page": "1974", "response": ["* September 1 \u2013 Mary Broadfoot Walker, Scottish physician (b. 1888)"]}, {"page": "Wigtown", "response": ["* Mary Broadfoot Walker, a physician noted for first demonstrating the effectiveness of physostigmine in treating myasthenia gravis."]}, {"page": "Mary Walker", "response": ["* Mary Broadfoot Walker (1888\u20131974), British physician"]}, {"page": "St Alfege's Hospital", "response": ["In 1934, while working at St Alfege's, Mary Broadfoot Walker first demonstrated the effectiveness of physostigmine in the treatment of the condition myasthenia gravis."]}]}}